65 DAFTAR PUSTAKA
1. Antoniou A, Pharaoh PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet.2003;72(5):1117-30
2. World Cancer Research Fund / American Institute for Cancer Research. Continuous Update Project Report. Food, Nutrition, Physical Activity, and the Prevention of Ovarian Cancer 2014. Available athttp://www.dietandcancerreport.org/cup/cup_resources.php
3. Jemal A, Siegel R, Ward E et al. Cancer statistics. CA Cancer J. Clin. 2008; 58(2):71–96.
4. du Bois A, Rochon J, Pfisterer J, Hoskins WJ. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol Oncol.2009;112:422-36.
5. Palmer C, et al. Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS One.2008;3:e2633
6. Blast L. Antigen cancer CA-125 in ovarian cancer. Am J Hum Genet.1983;2
7. Zurawski VR, et al. An initial analysis of preoperative serum CA-125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol.1988;30:7-14
8. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA-125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynecol.1990;97:922-9
9. Van Holsbeke C, et al. Ultrasound methods to distinguish between malignant and benign adnexal masses in the hands of examiners with different levels of experience. Ultrasound Obstet Gynecol.2009;34:454-61.
66 11. Zetter BR. Angiogenesis and tumor metastatis. Children’s Hospital.
Harvard Medical School. Boston. Massachusetts.1998;49:407-27
12. Oklu R, Walker TG, Wicky S, Hesketh R. Angiogenesis and current antiangiogenic strategies for the treatment of cancer. Department of Biochemistry University of Cambrige. United Kingdom.2010;21:1971-1805
13. Eskens FA. Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer.2004;90:1-7.
14. Hazelton D, Nicosia RF, Nicosia SV. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin Cancer Res.1999;5(4):823-9.
15. Yabushita H, Noguchi M, Obayashi Y, Kishida T, Noguchi Y, Sawaguchi K, et al. Angiostatin expression in ovarian cancer. Oncol Rep.2003;10(5):1225-30.
16. Urano T, Chibber B. A., Castellino F. J. The reciprocal effects of epsilon-aminohexanoic acid and chloride ion on the activation of human [Glu1]plasminogen by human urokinase. Proc. Natl. Acad. Sci. U.S.A.1987;84:4031–4
17. Drenberg CD, Saunders BO, Wilbanks GD, Chen R, Nicosia RF, Kruk PA, et al. Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer. Gynecologic Oncology.2010;117:117-124.
18. Damayana S. Perbedaan kadar angiostatin urin pada tumor ovarium epitel jinak dan tumor ovarium epitel ganas. Tesis Peserta Pendidikan Dokter Spesialis Obstetri dan Ginekologi Universitas Sumatera Utara.2014.
19. Cunningham FG, Gant NF, Leveno KJ, Gilstrap LC, Hauth JC, Wenstrom KD. Obstetri Williams Edisi ke-21 Vol. 2. Jakarta : ECG; 2004. p. 934,1035-7.
20. Berek JS, Satima N. Ovarian and fallopian tube cancer. Berek & Novak’s Gynecology. Lippincott William and Wilkins. 14th ed. 2007: 1457-1503
21. WHO, GLOBOCAN, International agency of research and cancer.2008
67 23. Kurman RJ, Shih le-Ming. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol.2008;27(2):151-60
24. Brohet RM, Goldgar DE, Easton DF, et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS collaborating group. J Clin Oncol.2007;25:3831-6
25. Rostgaard K. Does pregnancy induce the shedding of premalignat ovarian cells? Epidemiology.2003;14:168-173
26. Whittermore AS. Characteristic relating to ovarian cancer risk, Collaborating ovarian cancer group. Am J Epidemiol.1992;136:1184-1203
27. Cannistra SA, Gershenson DM, Recht A. Ovarian cancer, peritoneal carcinoma and fallopian tube carcinoma. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and practice of oncology. 8th ed. Philadelpia, PA: Lippincott Williams & Wilkins; 2008:1569-94
28. Lynch HT, Casey MJ, Snyder CL, et al. Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology and management and hereditary nonpolyposis colorectal cancer (HNPCC). Mol Oncol.2009;3:97-137
29. Scully R, Sobin L. Histological typing of ovarian tumours, volume 9. New York: Springer Berlin,1999.
30. Saifuddin, Abdul Bari, dkk. Ilmu Kebidanan Sarwono Prawirohardjo. Jakarta: PT Bina Pustaka Sarwono Prawirohardjo. 2010.
31. Chen SS, Bochner R. Assesment of morbidity and mortality in primary cytoreductive surgery for advanced ovarian carcinoma. Gynecol Oncol.1985;20(2):190-5
32. Olivier RI, Lubsen-Brandsma MA, Verhoef S, et al. CA-125 and transvaginal ultrasound monitoring in high risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol.2006;100(1):20-26
68 34. Levine HA, Pamuk S, Sleeman BD, Hamilton MN. Mathematical Modelling of Tumour Angiogenesis and the Action of Angiostatin as a Protease Inhibitor. J Theoritical Med.2002; 4(2):133-45.
35. Shirakawa K, et al. Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer.2002;99:821–28
36. Baluk P, et al. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev.2005;15:102–11.
37. Cao Y. Therapeutic potentials of angiostatin in the treatment of cancer. Haematologica.1999;84:643-650.
38. Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nature Clin Prac Oncol.2006; 5:194-204.
39. Sim BKL, O'Reilly MS, Liang H, Fortier AH, He W, Madsen JW, et al. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res.1997;57:1329–34.
40. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med.1971;285(1):182-6.
41. Walter JJ, Sane DC. Angiostatin binds to smooth muscle cells in the coronary artery and inhibits smooth muscle cell proliferation and migration In vitro. ArteriosclerThromb Vasc Biol.1999;19:2041-8.
42. Morikawa W, Yamamoto K, Ishikawa S, Takemoto S, Ono M, Fukushi J, Naito S, Nozaki C, Iwanaga S, and Kuwano M. Angiostatin generation by cathepsin D secreted by human prostate carcinoma cells. J. Biol. Chem.2000;275: 38912–20.
43. Ji WR, Castellino FJ, Chang Y, Deford ME, Gray H, Villarreal X, et al. Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. FASEB.1998;12(15):1731-8.
44. Cao Y, Chen A, An SS, Ji RW, Davidson D, Llinas M: Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem.1997;272(36):22924-8.
45. Wahl ML, Kenan DJ, Gronow GM, Pizzo SV. Angiostatin's molecular mechanism: aspects of specificity and regulation elucidated. J Cell Biochem.2005;96(2):242-61.
69 47. Soff GA. Angiostatin and angiostatin-related proteins. Cancer
Metastasis Rev.2000;19(1-2):97-107.
48. O'Reilly MS. et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell.1994;79:315-28.
49. Cao R, Wu HL, Veitonmaki N, Linden P, Farnebo J, Shi GY, et al: Suppression of angiogenesis and tumor growth by the inhibitor K1–5 generated by plasmin-mediated proteolysis. Proc Natl Acad Sci USA.1999;96:5728-5733.
50. Schulter V, et al. Impact of apolipoprotein(a) on in vitro angiogenesis. Arterioscler Thromb Vasc Biol.2001;21:433-8.
51. Mowery YM, Pizzo SV. The antitumorigenic trifecta. Blood 2009;114(9):1727-8
52. Chi SL, Pizzo SV. Angiostatin Is Directly Cytotoxic to Tumor Cells at Low Extracellular pH: A Mechanism Dependent on Cell Surface– Associated ATP Synthase. Cancer Res.2006;66(2): 875-82.
53. Benelli R, Morini M, Carrozzino F, Ferrari N, Minghelli S, Santi L, et al: Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J.2002;16:267-269.
54. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol.2000;2:737-744.
55. Hajitou A, Grignet C, Devy L, Berndt S, Blacher S, Deroanne CF, et al. The antitumoal effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J.2002;1:1096-1102.
56. Redlitz A, Daum G, & Sage EH. Angiostatin diminishes activation of the mitogen activated protein kinases ERK-1 and ERIC-2 in human dermal microvascular endothelial cells. J Vase Res.1999;36:28-34.
57. Lucas R, et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood.1998;92:4730-41.
70 59. Veitonmaki N. et al. Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for kl-5-induced antiangiogenesis. Cancer Res 2004;64:3679-86.
60. Lee TY, Muschal S, Pravda EA, Folkman J, Abdollahi A, Javaherian K. Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins. Blood 2009;114(9):1987-98.
61. Troyanovsky B, Levchenko T, Mansson G, Matvijenko O, Holmgren L. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol.2001;152:1247-54.
62. Tarui T, Miles LA, Takada Y. Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells. J Biol Chem.2001;276:39562-8
63. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nut Med.1996;2:689-92.
64. Sten-Linder M, et al. Angiostatin fragments in urine from patients with malignant disease. Anticancer Res.1999;19:3409-14.
65. Cao Y, et al. Elevated levels of urine angiostatin and plasminogen/plasmin in cancer patients. Int JMol Med.2000;5:547-51.
66. Dahlan MS. Penelitian diagnostik: dasar-dasar teoretis dan aplikasi dengan program SPSS dan Stata. Jakarta: Salemba Medika,2009:34
67. RayBio Human Angiostatin ELISA Kit Protocol. RayBiotech, Inc. User Manual (Revised Mar 1, 2012)
